Food & Drug Administration Commissioner David A. Kessler's activist approach to drug regulation is running into flak within the Administration. The White House thinks he's going too far in his crackdown on companies that promote the use of prescription drugs for unapproved purposes. "It's incredibly paternalistic," grouses one aide. "It assumes that doctors don't know what they are doing." But so far, Kessler has not been ordered to back off.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.